Damian Marron

Biography

  Mr. Damian Marron, Ph.D. is an Entrepreneur-In-Residence at Loxbridge Research LLP. Mr. Marron serves as Chief Executive Officer of Agalimmune Limited. He served as the Chief Executive Officer of TxCell Promesses from October, 2013 to April 2015 where he led a successful IPO in April 2014 on the Paris Euronext exchange. Mr. Marron served as Chief Executive Officer of Cytheris SA from 2012 to 2013. Mr. Marron served as Chief Executive Officer of Trophos SA since June 2008 until 2012. He served as chairman and Executive Vice President of Corporate Development of Nicox SA from 2002 to May 30, 2008. He held various corporate, business development and operational roles at NicOx SA, 3M Pharmaceuticals, Orphan Europe, Rhone-Poulenc-Rorer and Glaxo. He served as Head of the European division of Development Business at 3M Pharmaceuticals since 1997, where he responsible for several Distribution and licensing agreements. From 1995 to 1997, Mr. Marron occupied the position of Person in charge for the Office of the United Kingdom within Orphan Europe, it specialized in the orphan drugs. From 1992 to 1995, he served with Rhône-Poulenc Rorer, initially like Coordinateur of Research Clinical Senior in oncology then like Responsable for the Clinical Operations within joint venture the Chugai-Rhone-Poulenc. From 1987 to 1992, he occupied the functions of attache of Research Clinical in the field of the central nervous system and of researcher in cellular biology at Glaxo. Mr. Marron served as a Director of TxCell Promesses until April 2015. Mr. Marron has over 20 years biotechnology and pharmaceutical industry experience. He is a highly experienced executive with strong experience in orphan diseases. He is an accomplished serial biotech Chief Executive Officer and non-executive director with a track record of value creation and leadership in public and private biotech companies. He has raised well in excess of £200M in public and private equity and non-dilutive financing. He has great experience of pharmaceutical industry at the international level, in particular in the fields of the licenses, research and development and of the sale/sellings and marketing. He serves as Director at Loxbridge Research LLP. He has been an Independent Director at Bone Therapeutics SA since JUne 9, 2017. Mr. Marron obtained his diploma in pharmacology with mention of the University of Liverpool in 1985 and supplemented by research tasks in the field of the monoclonal antibodies within the service of cancerous radiotherapy of the University. He holds a BsC in pharmacology with post-graduate experience in cell biology.

Research Interest

  pharmacology